Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results

Basit Öğe Kaydı
dc.authorscopusid36627990300
dc.authorscopusid55568401300
dc.authorscopusid56048316800
dc.authorscopusid50263136900
dc.authorscopusid6507235676
dc.authorscopusid36864558700
dc.authorscopusid57211246733
dc.contributor.authorÇakır, Akin
dc.contributor.authorErden, Burak
dc.contributor.authorBölükbaşı, Selim
dc.contributor.authorSever, Özkan
dc.contributor.authorErkul, Sezin Ozdogan
dc.contributor.authorOsmanbasoglu, Ozen Ayranci
dc.contributor.authorElcioğlu, Mustafa Nuri
dc.date.accessioned2022-05-11T14:35:47Z
dc.date.available2022-05-11T14:35:47Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: To compare the efficacy of three initial monthly intravitreal aflibercept injections followed by pro re nata (3+PRN) dosing versus five initial monthly intravitreal aflibercept injections followed by pro re nata (5+ PRN) dosing in patients with diabetic macular edema. Methods: A total of 60 treatment-naive patients with macular edema who underwent intravitreal aflibercept injections (2 mg/0.05 mL) with at least one year of follow-up were analyzed in this retrospective and comparative study. The patients were divided into two groups according to the number of intravitreal aflibercept injections administered in the loading phase. The 3+PRN group comprised 27 patients, whereas the 5+PRN group comprised 33 patients. The visual and anatomical outcomes were compared between the two groups at baseline and at 3, 6, 9, and 12 months. Results: Both 3+ PRN and 5+ PRN, showed statistically significant improvements in the best-corrected visual acuity and central macular thicknesse throughout the study period (p<0.001 and, p < 0.001, respectively). There were no significant differences between the two groups in terms of changes in the best-corrected visual acuity and central macular thickness (p=0.453 and, p=0.784, respectively). The mean number of intravitreal aflibercept injections was significantly greater in the 5+PRN group (6.1 +/- 0.8) than in the 3+PRN group (3.9 +/- 0.8) (p<0.001). Conclusion: The 3+PRN and 5+PRN regimens showed similar 12-month visual and anatomical outcomes following treatment with intravitreal aflibercept injections in patients with macular edema.
dc.identifier.doi10.5935/0004-2749.20200078
dc.identifier.endpage401
dc.identifier.issn0004-2749
dc.identifier.issn1678-2925
dc.identifier.issue5en_US
dc.identifier.pmid33084817
dc.identifier.scopus2-s2.0-85094220872
dc.identifier.scopusqualityQ3
dc.identifier.startpage396
dc.identifier.urihttps://doi.org/10.5935/0004-2749.20200078
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8224
dc.identifier.volume83
dc.identifier.wosWOS:000581742700008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSever, Özkan
dc.language.isoen
dc.publisherConsel Brasil Oftalmologia
dc.relation.ispartofArquivos Brasileiros De Oftalmologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiabetic retinopathy
dc.subjectMacular edema
dc.subjectIntravitreal injections
dc.subjectReceptors
dc.subjectvascular endothelial growth factor/administration & dosage
dc.subjectEndothelial Growth-Factor
dc.subjectVegf Trap-Eye
dc.subjectDa Vinci
dc.subjectRanibizumab
dc.subjectSociety
dc.titleThree versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8224.pdf
Boyut:
334.85 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu